Tarsus director settles 2,954 RSUs into shares
LINK WILLIAM J PHD reported acquisition or exercise transactions in this Form 4 filing.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
LINK WILLIAM J PHD reported acquisition or exercise transactions in this Form 4 filing.
Tarsus Pharmaceuticals, Inc. director William J. Link, PhD received 2,954 shares of common stock through the settlement of an equal number of vested Restricted Stock Units. These RSUs were granted on June 12, 2025 for his service as a non-employee director and vested after one year. Following this automatic equity settlement, he directly holds 119,286 common shares, with no shares sold or withheld for taxes in this Form 4.
Insider Trade Summary
2,954 shares exercised/converted
Exercise
2 txns
Insider
LINK WILLIAM J PHD
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 2,954 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,954 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 0 units (Direct);
Common Stock — 119,286 shares (Direct)
Footnotes (3)
- F1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
- F2. Each RSU represents a contingent right to receive one share of the Company's common stock.
- F3. RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
Key Figures
RSUs settled: 2,954 units
Common shares received: 2,954 shares
Holdings after transaction: 119,286 shares
+2 more
5 metrics
RSUs settled
2,954 units
Restricted Stock Units converted to common stock on June 12, 2026
Common shares received
2,954 shares
Shares issued upon RSU settlement for non-employee director
Holdings after transaction
119,286 shares
Total direct common stock ownership after RSU conversion
RSU grant date
June 12, 2025
Grant date for RSUs linked to non-employee director service
RSU vesting period
1 year
RSUs vest in full one year after grant, subject to service
Key Terms
Restricted Stock Units, contingent right, non-employee director, derivative security
4 terms
Restricted Stock Units financial
"The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs")."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Company's common stock."
non-employee director financial
"RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director..."
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Tarsus Pharmaceuticals (TARS) report for William J. Link?
Tarsus Pharmaceuticals reported that director William J. Link, PhD acquired 2,954 common shares via settlement of vested RSUs. These Restricted Stock Units converted into the same number of shares upon vesting, reflecting routine equity compensation rather than an open-market stock purchase or sale.
Was the Tarsus Pharmaceuticals (TARS) Form 4 an open-market buy or sale?
The Form 4 does not show an open-market buy or sale. It records an exercise/conversion of 2,954 Restricted Stock Units into common stock at $0.00 per unit, representing routine settlement of equity compensation rather than a discretionary market trade.
What are the terms of the RSUs reported in the Tarsus (TARS) Form 4?
The RSUs were granted on June 12, 2025 in connection with William J. Link’s service as a non-employee director. According to the footnotes, the units vest in full on the one-year anniversary of the grant date, subject to his continuous service on the board.
How many Restricted Stock Units were converted in the latest Tarsus Pharmaceuticals (TARS) insider filing?
The insider filing shows that 2,954 Restricted Stock Units were converted into 2,954 shares of Tarsus Pharmaceuticals common stock. Each RSU represented a contingent right to receive one share, and all units reported were fully settled in this transaction.
Did the Tarsus Pharmaceuticals (TARS) director retain any RSUs after this transaction?
No RSUs remain from this specific grant after the transaction. The derivative line in the Form 4 shows 2,954 Restricted Stock Units exercised or converted, with zero RSUs of that grant remaining outstanding, while the resulting common shares are now held directly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
